Onesource Specialty Pharma Ltd share price
Onesource Specialty Pharma Ltd (ONESOURCE) is a stock listed on India's exchanges (NSE & BSE). On Traddx you can view its live price, interactive candlestick charts with 20/50/200-day moving averages and golden/death-cross detection, quarterly results, analyst price targets, peer comparison, and the smart-money signal — which star investors hold it and who is buying it on today's bulk/block deals tape.
Onesource Specialty Pharma Limited value chain — customers, suppliers & competitors
OneSource Specialty Pharma is a contract development and manufacturing organization (CDMO) that specializes in biological drug products, particularly injectable formats and end-to-end clinical development. It sits between raw material chemical/biotech suppliers and global pharmaceutical companies seeking outsourced manufacturing.
🛒 Customers — who buys from Onesource Specialty Pharma Limited
- Global Pharmaceutical Companies — Contract manufacturing and CDMO services for biologics and injectables
⛓️ Suppliers — raw materials & inputs
- Active Pharmaceutical Ingredients (APIs) — Raw chemical and biological compounds
- Specialty Glass Vials and Packaging — Sterile containers for injectable formats
⚔️ Competitors — other sellers
- Lupin — Competes in specialty pharmaceuticals and complex injectables, with a much larger global scale.
- Indoco Remedies — Competes in formulation development and contract manufacturing services.
🔀 Other suppliers to its customers
- Lonza Group — Global CDMO giant that alternative pharmaceutical clients use for biological manufacturing.
- Catalent — Major international provider of delivery technologies and development solutions.
🤝 Peers that share its suppliers
- Dr. Reddy's Laboratories — Purchases similar chemical inputs and packaging materials for injectables production.
- Cipla — Shares common raw material and packaging vendors in the Indian pharmaceutical ecosystem.
This value-chain map is AI-researched from public sources; company links and any figures are estimates, not official company disclosures. Not investment advice.